Medtronic highlights global performance of MiniMed 780G
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world.
Stay updated with breaking news from Robert Vigersky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world.
Hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.
A special 13-article supplement to the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) examines the "Development and Future of Automated Insulin Delivery (AID) Systems.
With CE Mark approval, the benefits of the MiniMed™ 780G system are now available with a new sensor that takes less than 10 seconds to insert1 DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc ,...
Medtronic (NYSE:MDT) named its next-generation "Simplera" continuous glucose monitor (CGM) as a nod to its simplicity.